CURRICULUM VITAE - Bobby V. Khan, M.D., Ph.D.

Work Address:	Emory University School of Medicine Division of Cardiology 69 Jesse Hill Drive SE #C247 Atlanta, Georgia 30303 (404) 686-5500, #14607
Birthdate:	September 15, 1964
Birthplace:	Johnson City, New York
Marital Status:	Married (wife, Rebecca Talaiver Khan), one daughter
Education:	M.D. (with honors), Ph.D.	University of Tennessee-Memphis Memphis, Tennessee 1984-1990 Ph.D. major: Pharmacology
	B.A. (magna cum laude)	Vanderbilt University Nashville, Tennessee 1981-1984 B.A. major: Chemistry
Post-Graduate Training:	INTERNSHIP	Internal Medicine, UCLA Medical Center Los Angeles, California 1990-1991
	RESIDENCY	Internal Medicine, UCLA Medical Center Los Angeles, California 1991-1993
	FELLOWSHIP	Cardiology, Emory University Atlanta, Georgia 1993-1996
Professional:	1997-present	Assistant Professor of Medicine/Cardiology Research Assistant Professor of Gynecology/Obstetrics Emory University School of Medicine Atlanta, Georgia Staff Physician, Department of Cardiology Director, Coronary Care Unit Grady Memorial Hospital Atlanta, Georgia
Certification:	Georgia medical license #37251 DEA #BK 3070935 American Board of Internal Medicine, September 1993 (#152902)
Honors:	Phi Beta Kappa honorary, Vanderbilt University (1984) American Diabetes Association Investigator�s Award (1987) Alpha Omega Alpha honorary, University of Tennessee (1990) Solomon Scholars Research Award, UCLA (1993) American Heart Association Young Investigator�s Award (1994)
Research:	Second messenger systems involved in the inflammatory mechanisms of atherogenesis (1993-2002) Collaborators: R. Wayne Alexander and Sampath Parthasarathy Supported by: NIH Clinical Investigator Award ($308,109 total) Principal Investigator: Bobby V. Khan Clinical studies investigating accelerated forms of coronary artery disease (1998-present) Collaborators: Sampath Parthasarathy Supported by: Research sources from Pfizer Pharmaceuticals and Solvay Pharmaceuticals ($86,000 total) Principal Investigator: Bobby V. Khan
Invited Reviewer for Following Scientific Journals: Circulation/Circulation Research Journal of the American College of Cardiology Arteriosclerosis, Thrombosis, and Vascular Biology Journal of Clinical Investigation European Heart Journal

BIBLIOGRAPHY

Manuscripts

1. Khan BV, Wilcox HG, and Heimberg M.Lovastatin suppresses VLDL metabolism by the liver in the perfused rat liver model. Biochem. J. 254:809-816 (1989).

2. Khan BV, Fungwe TV, Wilcox HG, and Heimberg M.Cholesterol suppression reduces VLDL synthesis: in vivo studies. Biochim. Biophys. Acta 49: 2056-2061 (1990).

3. Khan BV, Parthasarathy S, Alexander RW, and Medford RM. Modified forms of low density lipoprotein induces cytokine-activated VCAM-1 and ICAM-1. J. Clin. Invest. 84:1262-1270 (1995).

4. Khan BV, Harrison DG, Alexander RW, and Medford RM. Nitric oxide analogues suppress VCAM-1 gene expression in human vascular endothelial cells. Proc. Natl. Acad. Sci. USA 74:1051-1055 (1996).

5. Yerneni KKV, Bai W, Khan BV, Medford RM, and Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kB in vascular smooth muscle cells. Diabetes 48:855-864 (1999).

6. Navalkar S, Santanam N, and Parthasarathy S, and Khan BV. Angiotensin Type 1 receptor inhibitors suppress inflammatory markers in patients with early atherosclerosis. �J. Am. Coll. Cardiol. 37:440-444(2001).

7. Yerneni KKV, Malik KU, Khan BV, and Natarajan R. Activation of second messenger systems by human aortic smooth muscle cells in high glucose conditions. Arter Thromb Vasc Biol 21:1408-1413 (2001).

8. Khan BV, Navalkar S, Rahman ST, Khan QA, Parthasarathy S.Irbesartan, an angiotensin type 1 receptor inhibitor, regulates pro-oxidation species in patients with coronary artery disease.J. Am. Coll. Cardiol. 38:1662-1667 (2001).

9. Khan BV, Lauten WB, Navalkar S, Khan QA, Rahman ST, and Parthasarathy S. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure. Am. J. Cardiol. 89:363-367 (2002).

10. Lauten WB, Khan QA, Rahman ST, Parthasarathy S, Lerakis S, and Khan BV. Inhibitors of the renin-angiotensin system potentiate the anti-inflammatory effects of statins in the vasculature of patients with coronary artery disease. Am J Cardiol. 91:1116-1119 (2003).

Abstracts (31 in publication, 20 first-authored)�last 3 are listed

1. Khan BV, Parthasarathy S, Santanam N, and Alexander RW. Oxidized forms of low density lipoprotein regulate phospholipase D activity in human aortic endothelial cells.Presented at the American Heart Association Scientific Sessions, Dallas, Texas (2000).

2. Khan BV, Navalkar S, Santanam N, Parthasarathy S, and Alexander RW.Activation of inflammatory vascular markers in patients with premature coronary artery disease.Presented at the American College of Cardiology Scientific Sessions, Anaheim, California (2001).

3. Khan BV, Lauten WB, Khan QA, Rahman ST, and Parthasarathy S. Inhibitors of the renin-angiotensin system potentiate the anti-inflammatory effects of statins in the vasculature of patients with coronary artery disease. Presented at the American College of Cardiology Scientific Sessions, Atlanta, Georgia(2002).